Gilead's latest Covid study finds mixed results for 'moderate' patients — and that may be good

The marquee drug in the fight against Covid-19 helped most "moderate" Covid pneumonia patients improve after five days but those treated over 10 days did not see an improvement that was statistically significant. Covid pneumonia patients who didn't require ventilation and were given remdesivir from based Gilead Sciences Inc. (NASDAQ: GILD) over five days were 65% more likely to see clinical improvement after 11 days than those who received standard of care, the Foster City-based company said Monday.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news